Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of Microport sirolimus drug coated balloon catheter for the treatment of coronary bifurcation lesions.
PROMISE-BIF is a prospective, multicenter, randomized controlled, non-inferior clinical trial, which would enroll about 234 participants. All participants will undergo PCI with sirolimus drug coated balloon catheter or paclitaxel drug coated balloon catheter and be followed-up to 24 months.
The Target Lesion defined as the true bifurcation, include the main branch and side branch lesion.
The bifurcation lesions were classified by Medina (1.1.1, 1.0.1, and 0.1.1). The image data will be analyzed and evaluated independently by a third-party imaging laboratory.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sirolimus coated balloon catheter | Experimental | Manufacturer: Shanghai MicroPort Medical Group Co, Ltd. |
|
| Paclitaxel coated balloon catheter | Active Comparator | Manufacturer: Liaoning Yinyi Biotechnology Co., Ltd |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PCI | Procedure | Patients in experimental group will undergo PCI with drug coated balloon catheter to treat the side branch of the coronary bifurcation lesion. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent Diameter Stenosis (DS) of side branch | Stenosis of lumen diameter of lesion segment of the side branch | 9 months |
| Measure | Description | Time Frame |
|---|---|---|
| Late lumen loss (LLL) of side branch | late lumen loss of lesion segment of the side branch | 9 months |
| Measure | Description | Time Frame |
|---|---|---|
| Immediate Success Endpoint | Immediate Success Endpoint including Technical success, Lesion success and Procedural success. Technical success defined as the success of the study device in reaching the target lesion branch vascular lesions, dilatating and retracting successfully with residual stenosis of the branch vessel lesion ≤30%(visual inspection); Lesion success defined as the main and branch vessels of the target lesion residual stenosis Residual stenosis ≤ ≤30%, furthermore blood flow is TIMI 3 (visual inspection) after treatment with any interventional method Procedural success defined as the absence of device-related composite end point events during the hospitalization period (up to 7 days after surgery) on the basis of Lesion success. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| General Hospital of the PLA Northern Theater Command | Shengyang | Liaoning | China |
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 7 days |
| DoCE | Defined as a composite of cardiac death, target vessel-related MI, or ischemia-driven side branch lesion revascularization events at 30 days, 6 months, 9 months and 12 months | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| PoCE | Defined as a composite rate of all cause death, all MI or any revasculariztion at 30 days, 6 months, 9 months, and 12 months | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| Death | Cardiac, Vascular, Non-cardiovascular related | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| Myocardial infarction | Target vessel related, Non-target vessel related | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| Target lesion Revascularization | Lesion revascularization in main branch, side branch or both, ischemic driven or non-ischemic driven | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| Target vessel Revascularization | Ischemia-driven , Not ischemia-driven | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| Any coronary revascularization | Ischemia-driven , Not ischemia-driven | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| Thrombotic events | ARC defined: acute, subacute, late | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| AE & SAEs rate | 30 days, 6 months, 9 months, 12 months, 24 months post-procedure |
| side branch re-stenosis rate | the proportion of patients with re-stenosis in the side branch, stenosis degree >50% | 9 months |
| main branch re-stenosis rate | the proportion of patients with re-stenosis in the main branch, stenosis degree >50% | 9 months |
| In-segment late loss of the main branch (mm) | The minimum lumen diameter (MLD) immediately after stent implantation was subtracted from the MLD at follow-up | 9 months |
| In-segment Stenosis degree of the main branch (%) | 9 months |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |